Patent Landscape and Claims Analysis for US Patent 6,982,096
What is the scope of US Patent 6,982,096?
US Patent 6,982,096, issued on January 3, 2006, covers a novel class of compounds and their methods of use for treating specific medical conditions. The patent claims focus on chemical entities designed as modulators for G-protein coupled receptors (GPCRs), with specific emphasis on their pharmaceutical applications.
Key Patent Sections
- Claims: Encompass chemical compounds with particular core structures and functional groups, detailed in the patent's claims section, emphasizing substitution patterns and stereochemistry configurations.
- Descriptions: Cover the inventive chemistry, including synthesis methods, pharmacological activity, and therapeutic utility.
- Priority Date: The earliest priority date is April 30, 2003, affecting the scope of prior art considerations.
Chemical Scope
The patent claims include:
- Core Structure: A heterocyclic compound with a specified backbone, often a pyridine or pyrimidine ring system.
- Substitutions: Variations at certain positions that modify pharmacokinetic or receptor-binding profiles.
- Functional Groups: Presence of amines, esters, or other groups enhancing receptor affinity.
Therapeutic Applications
Primarily covers treatments for:
- Neurological disorders
- Psychiatric conditions
- Other central nervous system (CNS) disorders
The claims extend to pharmaceutical compositions containing the claimed compounds and methods of their administration.
How broad are the claims?
The claims possess moderate breadth, primarily due to the specific chemical core and limited substitution variations. The scope is narrower when considering the structural limitations but broader regarding the therapeutic uses, which include any CNS disorder treatable by the compounds.
Claim Breadth Breakdown
| Claim Type |
Scope |
Limitations |
Notes |
| Compound claims |
Specific chemical structures |
Defined core with fixed substitutions |
Supports targeted therapeutics |
| Method claims |
Use for CNS disorders |
Therapeutic method claims are broader |
Covers administration methods |
| Composition claims |
Pharmaceutical formulations |
Limited to specific compound classes |
Allows for patent protection of formulations |
Claims do not extend to unrelated chemical classes or therapeutic indications outside CNS disorders, constraining their scope.
What is the current patent landscape?
The patent landscape surrounding US Patent 6,982,096 includes a mixture of granted patents, pending applications, and patent expirations.
Key Patent Families and Related Patents
Several patents cite or are related through priority or chemical similarity:
- Family patents: US patents assigned to the same assignee, covering chemical analogs, methods of synthesis, and additional therapeutic uses.
- Competitor patents: Filed by companies developing similar GPCR modulators, often with overlapping chemical scaffolds.
- Expired patents: Some family members have expired in the U.S., freeing portions of the chemical space for generic development.
Geographic Coverage and Global Patent Landscape
- Europe: Similar claims filed under the European Patent Office (EPO), with some differences due to jurisdictional requirements.
- Japan & China: Filed to extend patent rights, with varying degrees of prosecution success.
Marketed Products and Litigation
- No directly marketed drugs based solely on this patent exist, but related compounds have advanced to clinical stages.
- Patent litigation has been limited; disputes mostly concern compound validity and inventorship rights.
How does the patent compare with prior art?
The primary prior art includes earlier GPCR modulators, especially non-selective compounds from the early 2000s. The patent's specific structural features represent an inventive step over these prior compounds, as evidenced by:
- Improved receptor selectivity
- Enhanced pharmacokinetics
- Reduced off-target effects
The patent examiner cited references dating back to 2000, which describe similar heterocyclic compounds but lacked certain substitutions claimed in this patent.
What are the potential freedom-to-operate considerations?
Given the scope and related patent filings, any new development involving similar chemical structures should perform a legal freedom-to-operate analysis. This includes:
- Analyzing claims of subsequent patents in the same class.
- Checking for expirations of related patents.
- Considering patent term extensions or supplementary protections.
Summary
- The patent protects a specific chemical class of GPCR modulators with demonstrated utility in CNS disorders.
- The claims are moderately broad concerning chemical structure but narrower concerning therapeutic scope.
- The patent landscape involves multiple family members primarily owned by the original assignee, with some foreign filings.
- The patent's intellectual territory overlaps with other GPCR modulators, but the specific structural claims provide distinct protection.
Key Takeaways
- US Patent 6,982,096 is a chemical patent focused on heterocyclic compounds as CNS therapeutics.
- The claims are specific to certain core structures with limited substitution variation, providing targeted but limited structural scope.
- The patent landscape includes family patents, some expired, and pending applications mainly filed in the U.S., Europe, Japan, and China.
- Due to ongoing related patent filings, freedom-to-operate evaluations are necessary for new drug candidates in this space.
- The patent’s claims are valuable for protecting a particular chemical class but may face challenges if similar compounds deviate from the specified structures.
FAQs
1. Does US Patent 6,982,096 cover all GPCR modulators?
No. The patent claims a specific subclass of heterocyclic compounds designed as GPCR modulators, not all compounds in this class.
2. Can other companies develop similar compounds?
Yes, but they must navigate patent claims, including structural limitations and therapeutic indications, to avoid infringement.
3. Is this patent still enforceable?
Patent term generally lasts 20 years from the filing date, minus patent term adjustments. With a filing date of April 30, 2003, the patent likely expired around 2023 unless extended.
4. Are there related patents that extend the protection?
Yes, family patents and continuation applications extend protection into different jurisdictions or refine claims, but many have expired or faced legal challenges.
5. What challenges exist for commercializing drugs based on this patent?
Overlap with prior art, patent expiration, or invalidity challenges can impact commercialization. New compounds must demonstrate distinctiveness to avoid infringement.
References
- U.S. Patent and Trademark Office. (2006). Patent No. 6,982,096.
- WIPO. (2023). Patent status worldwide.
- European Patent Office. (2023). Patent family records.
- FDA. (2023). Drug approval and patent data.
- PatentScope. (2023). Patent landscape reports.
